Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
Added By: Feedage Forager Feedage Grade B rated
Language: English
announced  cancer  clinical  company  dec  december  marketwired dec  marketwired december  marketwired  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech

Marketwired - Biotech

Last Build Date: Wed, 07 Dec 2016 10:40:58 EST

Copyright: Copyright: (C) Marketwired

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene for Breast Cancer Treatment

Wed, 07 Dec 2016 10:31:19 EST

Women's oncology pharmaceutical company also raises more than $2 million in preferred seed funding round

Acquisitions are In-Vogue for Largest Medical Device Manufacturers

Wed, 07 Dec 2016 09:09:00 EST

Breakdown of Medical Device Acquisitions Reveals Industry Strategy

GeoVax to Conduct Investor and Partnering Meetings During 35th Annual J.P. Morgan Healthcare Conference

Wed, 07 Dec 2016 09:00:00 EST

ATLANTA, GA--(Marketwired - Dec 7, 2016) -  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is scheduling investor and corporate partnering meetings during the 35th Annual J.P. Morgan Healthcare Conference, to be held in San Francisco on January 9-12, 2017.

EnWave Announces Organizational Changes for NutraDried LLP

Wed, 07 Dec 2016 09:00:00 EST

VANCOUVER, BC--(Marketwired - December 07, 2016) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") is pleased to announce several organizational changes regarding NutraDried LLP ("NutraDried"), its 51% owned subsidiary that manufactures and distributes Moon Cheese®. EnWave confirms that NutraDried and Spire Brands, LLC ("Spire") have terminated the Master Supply and Distribution Agreement (the "MDA") between the two companies. The MDA was in operation for over one year and after a careful review, both parties concluded the MDA is not serving the best interests of either party. As a result of the termination, NutraDried will overtake the marketing and distribution strategy for its all natural cheese snack product, Moon Cheese®.

Model N Announces the Winter '16-17 Release, Transforming its Revenue Management Solutions for High Tech

Wed, 07 Dec 2016 09:00:00 EST

Channel Data Management Now Integrates with Revenue Enterprise Cloud to Enhance Data Collection Processes, Price More Effectively and Drive Long Term Revenue

Centralized Adaptive Trial Design Teams Promote Cross-Geography Communication

Wed, 07 Dec 2016 08:36:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - December 07, 2016) - A recent study released by Cutting Edge Information found that most surveyed clinical trial teams -- either global or at the country level -- report better cross-geography communication through centralized adaptive trial design decision-making structures. Establishing these centralized structures helps influence active dialogue between global and country-level teams.

OncBioMune Provides Update on Acquisition of Vitel Laboratorios

Wed, 07 Dec 2016 08:30:00 EST

BATON ROUGE, LA--(Marketwired - December 07, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides shareholders an update on the proposed acquisition of Vitel Laboratorios, S.A. de C.V. ("Vitel"), a revenue-stage Mexico-based pharmaceutical company that develops and commercializes high specialty drugs in Mexico and other Latin American countries.

Accomplished Healthcare Executive Jim Lang Invests and Joins BioVie's Board of Directors

Wed, 07 Dec 2016 08:00:00 EST

BEVERLY, MA--(Marketwired - December 07, 2016) - BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of Mr. James Lang as an independent member of the Company's Board of Directors. Mr. Lang is an active investor in emerging healthcare companies, and recently invested in BioVie.

DiaMedica Expands its Business Development Capabilities

Wed, 07 Dec 2016 08:00:00 EST

MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 7, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) announced today it has engaged Outreach 99 LLC ("Outreach") to assist in the business development efforts of the Company. Paul Papi, Founder and President of Outreach 99 LLC, will personally direct the effort, acting as DiaMedica's Vice President of Business Development.

Tauriga Sciences, Inc. Reports Progress in Completing the Formulation of its First ColluMauxil Branded Product, a Cannabidiol "CBD" Infused Roll On for Muscle Tension Relief

Wed, 07 Dec 2016 07:45:00 EST

LOS ANGELES, CA--(Marketwired - Dec 7, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, has today announced that the Company has completed the formulation of RolLeaf, its proprietary CBD infused product targeting individuals who suffer from muscle tension. The Company has manufactured its first sample batch of the product. As previously disclosed, the Company is forming a new subsidiary called ColluMauxil Therapeutics LLC ("ColluMauxil") to focus on the development, marketing, and licensing of non-opioid products and product lines that specifically target muscle tension, a key component of pain.

3D Signatures Molecular Imaging Technology Shows Potential in Improving Management of Lung Cancer Patients With Multiple Lesions

Wed, 07 Dec 2016 07:00:00 EST

Preliminary results of an important collaborative initiative with IUCPQ presented at 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria

ITUS Announces Cchek(TM) Preliminary Cancer Patient Efficacy Study Results

Wed, 07 Dec 2016 06:45:00 EST

LOS ANGELES, CA--(Marketwired - December 07, 2016) - ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced preliminary results from its CchekT cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient's immunological response to a malignancy, the Company achieved Sensitivity of 92% and Specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients. During the initial phase of the study, which involved multiple experimental protocols and techniques for measuring immunological responses, the Company reviewed and analyzed data from a total of 315 patient samples, including 228 patients with varying stages of cancer, as well as blood samples from 87 healthy donors.

Natgas, Transportation Drive Northeast's 2017 Project Kickoffs, an Industrial Info News Alert

Wed, 07 Dec 2016 06:20:00 EST

SUGAR LAND, TX--(Marketwired - Dec 7, 2016) - Researched by Industrial Info Resources (Sugar Land, Texas) -- More calls for transportation-related infrastructure and natural gas-fired power generation are driving much of the U.S. Northeast region's planned project kickoffs for the coming year. Industrial Info is tracking $39.32 billion in active projects set to begin construction in the U.S. Northeast in 2017. More than 80% of the total can be attributed to just four industries: Industrial Manufacturing, Power, Oil & Gas Pipelines, and Chemical Processing.

Panther Biotechnology Receives Positive Feedback from the FDA

Wed, 07 Dec 2016 06:00:00 EST

HOUSTON, TX--(Marketwired - Dec 7, 2016) - Panther Biotechnology, Inc. (OTC PINK: PBYA) today announced that it has received positive feedback from the submission presented to the U.S. Food and Drug Administration ("FDA") pursuant to a Pre-IND (Investigational New Drug) meeting with the Division of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the FDA. The purpose of the requested meeting was to obtain FDA's input regarding Panther's plans for the development of TRF-DOX, Panther's novel transferrin-doxorubicin conjugate initially planned for the treatment of platinum-resistant ovarian cancer. In preparation for the meeting, Panther submitted a Pre-IND Package to FDA that described the information Panther intends on submitting in the TRF-DOX IND submission planned in 2017. The IND is the regulatory vehicle that will allow for the initiation of clinical trials with TRF-DOX initially for the treatment of ovarian cancer.

Applied DNA Sciences Continues Its Successful Program Protecting Automobiles in Scandinavia

Wed, 07 Dec 2016 05:30:00 EST

STONY BROOK, NY--(Marketwired - December 07, 2016) - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a provider of DNA-based supply-chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, is continuing its quest to protect automobiles in Scandinavia.

UPDATE - Prolacta Bioscience(R) Raises $35 Million in Mezzanine Financing

Tue, 06 Dec 2016 16:36:49 EST

CITY OF INDUSTRY, CA--(Marketwired - Dec 6, 2016) - Prolacta Bioscience®, the nation's leading provider of human milk-based neonatal nutritional products, today announced the closing of a $35 million mezzanine round of financing. The transaction was led by Essex Woodlands and included participation from Aisling Capital, with existing shareholder Health Evolution Partners. As part of the transaction, Martin Sutter, Co-Founder and Managing Director at Essex Woodlands, will join Prolacta's Board of Directors.

Applied DNA Sciences Reports Fiscal Fourth Quarter and Year End Results

Tue, 06 Dec 2016 16:05:00 EST

Company To Hold Conference Call and Webcast Today, Tuesday, December 6, 2016 at 4:30 PM EST

Thérapeutique Knight annonce la majoration du financement par acquisition ferme

Tue, 06 Dec 2016 15:23:38 EST

MONTRÉAL, QUÉBEC--(Marketwired - 6 déc. 2016) -

Medical Marijuana, Inc.'s Investment Company AXIM(R) Biotech Receives Approval From Medical Ethical Committee to Begin IBS Trial for CBD Product

Tue, 06 Dec 2016 12:00:00 EST

Company's Major Investment AXIM Biotech to Begin Study on Patients with IBS with the CanChew Plus(R) CBD-containing Chewing Gum

Knight Therapeutics Announces Increase to Bought Deal Financing

Tue, 06 Dec 2016 11:04:05 EST

MONTREAL, QUEBEC--(Marketwired - Dec. 6, 2016) -

Leap the Pond Predicts Accounting Professionals will Play a More Strategic Role in Business Growth in 2017

Tue, 06 Dec 2016 09:32:00 EST

Cloud, Analytics, AI to Enable Strategic Insight

Tetra Bio-Pharma Looks to Make Cannabis Affordable -- CFN Media

Tue, 06 Dec 2016 09:28:03 EST

SEATTLE, WA--(Marketwired - Dec 6, 2016) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and story covering Tetra Bio-Pharma Inc.'s (CSE: TBP) (OTC PINK: GRPOF) unique approach in using the natural cannabis plant, rather than synthetics, to develop pharmaceuticals based on the active ingredients in marijuana. The interview is with Ryan Brown, Tetra's Co-Founder and Vice President of Business Development.

LockPath wins 2016 GRC Value Award for IT Governance, Risk Management and Compliance

Tue, 06 Dec 2016 09:00:00 EST

Health IT Company Surescripts Realizes the Benefits of the Keylight Platform

EnWave Signs Technology Evaluation and License Option Agreement with Major European Dairy Processor

Tue, 06 Dec 2016 09:00:00 EST

VANCOUVER, BC--(Marketwired - December 06, 2016) - EnWave Corporation (TSX VENTURE: ENW)(FRANKFURT: E4U) ("EnWave", or the "Company") announces today that it has signed a Technology Evaluation and License Option Agreement (the "TELOA") with a Major European Dairy Processor (the "Research Partner") to explore the potential for dried dairy applications processed by the Company's patented Radiant Energy Vacuum ("REVT") dehydration technology. The Research Partner will have the exclusive option to license the use of REVT technology for the production dairy products within an agreed European territory for a period of six months.

ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting

Tue, 06 Dec 2016 08:45:38 EST

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - December 06, 2016) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced yesterday encouraging top-line results from the First in Man international multicenter Phase I clinical trial with RG6016 (a potent and selective inhibitor of lysine-specific histone demethylase-1, previously known as ORY-1001) in relapsed or refractory acute leukemia (RR-AL) patients (EUDRACT nº 2013-002447-29). Results were presented in a poster session at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California.

American Cannabis Company Announces It Has Secured a New Client for the Pennsylvania Medical Marijuana Dispensary Program

Tue, 06 Dec 2016 08:30:00 EST

DENVER, CO--(Marketwired - Dec 6, 2016) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has signed another client in Pennsylvania who will be applying for a dispensary license in the state's upcoming medical marijuana program. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements and potential sales of ancillary products.

Helix BioPharma Corp. Presents Topline L-DOS47 Results at the 17th IASCLC World Conference on Lung Cancer

Tue, 06 Dec 2016 08:30:00 EST

Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients

VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors

Tue, 06 Dec 2016 08:30:00 EST

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Dec. 6, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines, today announced that it has raised $23.6 million in concurrent equity and debt financing transactions with Perceptive Advisors.

Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials

Tue, 06 Dec 2016 08:30:00 EST

OTTAWA, ONTARIO--(Marketwired - Dec. 6, 2016) - Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE:TBP)(CSE:TBP.CN) and (OTC PINK:GRPOF) is conducting a non-brokered private placement with Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share of the Company at a price of $0.26 per share for a period of 3 years following the closing date. The warrants are subject to an accelerated expiry if the Company's shares trade above $0.45 for thirty (30) consecutive trading days then the warrants will expire in 30 days if not exercised.

Prolacta Bioscience(R) Raises $35 Million in Mezzanine Financing

Tue, 06 Dec 2016 08:30:00 EST

CITY OF INDUSTRY, CA--(Marketwired - Dec 6, 2016) - Prolacta Bioscience®, the nation's leading provider of human milk-based neonatal nutritional products, today announced the closing of a $35 million mezzanine round of financing. The transaction was led by Essex Woodlands and included participation from Aisling Capital, with existing shareholder Health Evolution Partners. As part of the transaction, Martin Sutter, Co-Founder and Managing Director at Essex Woodlands, will join Prolacta's Board of Directors.

Premier Biomedicals Research on its Patent Pending Anti-Cancer Treatment With Metronomic Chemotherapy Recognized for Publication in the Prestigious British Journal of Cancer

Tue, 06 Dec 2016 08:00:00 EST

EL PASO, TX--(Marketwired - Dec 6, 2016) -  Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for pain management, announced today that a paper describing their groundbreaking metronomic cancer therapy work in conjunction with development of a patent pending CTLA4 anti-cancer antibody drug at the University of Texas El Paso (UTEP) has been accepted for publication by the prestigious British Journal of Cancer.

NEW REPORT: Arizona Marijuana Sales to Top $681 Million by 2020 Despite Failure of Prop. 205

Tue, 06 Dec 2016 08:00:00 EST

WASHINGTON, DC--(Marketwired - December 06, 2016) - New Frontier Data, the cannabis Big Data and analytics authority, in partnership with Arcview Market Research, the leading publisher of cannabis market research has released its Arizona Legal Cannabis Market State Profile. Arizona's medical cannabis market sales are expected to total $367 million in 2016. Medical sales are projected to climb to $681 million by 2020 with a compound annual growth rate of 17%.* This 2020 projection is approximately half the projected 2020 sales if Proposition 205 had passed on Election Night.

NEW REPORT: Florida Marijuana Sales to Top $1.6 Billion by 2020

Tue, 06 Dec 2016 08:00:00 EST

Rocketing at a 140% Annual Growth Rate

Abeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School

Tue, 06 Dec 2016 07:43:00 EST

NEW YORK, NY and CLEVELAND, OH--(Marketwired - December 06, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, Ph.D., will participate in a panel discussion at the 2016 Genetic Rx Conference at the Harvard Medical School in Boston, MA.

Operational Excellence in Immuno-Oncology Clinical Trials, New Webinar Hosted by Xtalks

Tue, 06 Dec 2016 07:30:00 EST

As cancer treatments become more focused on personalized care for the patient, understanding the intricacies of immuno-oncology becomes increasingly important. Join our speakers who will outline how to manage the complexity of these studies and ways to maintain a successful partnership with your CRO

Hutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH

Tue, 06 Dec 2016 02:43:42 EST

HONG KONG, CHINA--(Marketwired - Dec 6, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

Golden Leaf Holdings Issues Shares to Settle Debt

Mon, 05 Dec 2016 20:13:32 EST

TORONTO, ON--(Marketwired - December 05, 2016) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, announced today that it has agreed to settle outstanding indebtedness of C$50,000 owed to a consultant retained by the Company to secure funding through the issuance of 150,000 common shares of the Company at a deemed price of C$0.333 per common share (the "Debt Settlement"). The common shares to be issued in connection with the Debt Settlement are subject to a four month hold period. The consultant is at arm's length to the Company.

Ogilvy CommonHealth Worldwide wins silver at 2016 Clio Health Awards

Mon, 05 Dec 2016 16:33:35 EST

PARSIPPANY, NJ--(Marketwired - Dec 5, 2016) - Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced the organization's Sydney-based office, Ogilvy CommonHealth Asia Pacific, has won a silver award at the 2016 Clio Health Awards competition.

More Positive Financial Results for Vivakor

Mon, 05 Dec 2016 15:42:23 EST

LAS VEGAS, NV--(Marketwired - December 05, 2016) - Vivakor Inc. (OTC PINK: VIVK) announced GAAP based financial results for the quarter ended September 30, 2016.

InspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday, December 6 at 4:30PM PT

Mon, 05 Dec 2016 15:17:39 EST

BOSTON, MA--(Marketwired - Dec 5, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a change in the Company's presentation time at the LD Micro 9th Annual Main Event on Tuesday, December 6 in Los Angeles, California. Chief Financial Officer, Craig Shore, will now present at 4:30pm PT. Mr. Shore will provide a corporate overview and discuss the Company's proprietary MicroNetT technology, which has been developed to address key issues found with current stenting options.

UniQuest and CCRM sign international deal to develop treatment for chemotherapy-induced neutropenia

Mon, 05 Dec 2016 14:00:00 EST

TORONTO, ON and BRISBANE, AUSTRALIA--(Marketwired - December 05, 2016) - Patients at risk of life-threatening infections following chemotherapy could benefit from a new cell-based treatment developed from University of Queensland research.

3D Signatures Adds Leading Commercial Diagnostics Lab Executive to Advisory Board

Mon, 05 Dec 2016 12:16:30 EST

WINNIPEG, MB--(Marketwired - December 05, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce the appointment of Mr. Nigel Terrett to 3DS' Business Advisory Board ("BAB"). Mr. Terrett will provide the Company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform. Mr. Terrett brings extensive commercial lab experience to 3DS which includes executive roles with several major commercial labs and electronic health record companies such as Excelleris Technologies, Lifelabs Inc. and MDS Diagnostics Inc.

Theratechnologies clôture son placement d'actions ordinaires

Mon, 05 Dec 2016 09:12:06 EST

MONTRÉAL, CANADA--(Marketwired - 5 déc. 2016) -

Theratechnologies closes its offering of common shares

Mon, 05 Dec 2016 09:10:52 EST

MONTREAL, CANADA--(Marketwired - Dec. 5, 2016) -

GeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses

Mon, 05 Dec 2016 09:00:00 EST

ATLANTA, GA--(Marketwired - Dec 5, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will give a talk at the Hemorrhagic Fever Viruses conference sponsored by the Keystone Symposia on Molecular and Cellular Biology. The conference is being held on December 4-8 in Santa Fe, New Mexico.

BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory

Mon, 05 Dec 2016 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC--(Marketwired - December 05, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company will present the latest development update for BriaVaxT, the Company's proprietary vaccine for advanced breast cancer, at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Additionally, the Company signed a service agreement contract with the Terasaki Foundation Laboratory, a leading non-profit research institution in the area of organ transplantation and immunology, based in Los Angeles.

HCi Viocare enters into discussions with New Balance Athletics, Inc.

Mon, 05 Dec 2016 08:27:07 EST

GLASGOW, SCOTLAND--(Marketwired - Dec 5, 2016) - HCi Viocare (OTCQB: VICA), is pleased to announce that it has entered into discussions with one of the major sport shoes manufacturers in the world, New Balance Athletics, Inc.

Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal

Mon, 05 Dec 2016 08:00:00 EST

BALTIMORE, MD--(Marketwired - December 05, 2016) - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced top-line clinical results from its nicotine withdrawal Phase 2 clinical trial of CERC-501, an oral, potent, and selective kappa opioid receptor ("KOR") antagonist. The trial did not meet its primary objective in nicotine withdrawal. CERC-501 was well tolerated. Based on this favorable side-effect profile, and as previously planned, Cerecor intends to move forward with development of CERC-501 in its primary indication, as an adjunctive treatment of Major Depressive Disorder (MDD).

Corbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony

Mon, 05 Dec 2016 07:00:00 EST

Company Celebrates the Recently Reported Positive Topline Results with Lead Drug Candidate, Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis

VoicePort Announces Partnership with iMedicare Inc.

Mon, 05 Dec 2016 07:00:00 EST

ROCHESTER, NY--(Marketwired - December 05, 2016) - VoicePort LLC and iMedicare announced an agreement today to provide community pharmacists with patient-specific Medicare plan analyses via VoicePort's CLAROT adherence application. The collaboration will allow current and future VoicePort clients the ability to access this valuable service and assist patients in making efficient and informed decisions when selecting a Medicare Advantage or Prescription Drug Plan.

Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

Sat, 03 Dec 2016 12:00:00 EST

SAN DIEGO, CALIFORNIA--(Marketwired - Dec. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with relapsed or refractory hematologic malignancies, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego.

SafetyChain Software's November FSMA Fridays Session Recording on Environmental Controls Now Available

Fri, 02 Dec 2016 11:10:00 EST

November FSMA Friday session featured The Acheson Group's Peyman Fatemi and Gurjit Shergill

New Advanced Antimicrobial Stewardship Solution from Wolters Kluwer Helps Healthcare Organizations Improve Clinical Outcomes, Reduce Costs

Fri, 02 Dec 2016 09:30:00 EST

Expanded Pharmacy OneSource Sentri7 Offering Powers High-Performing Antimicrobial Stewardship Programs to Address Growing Concerns Over Resistant Organisms

eWellness Announces Signing of Initial Third Party PT Clinic for its PHZIO Telemedicine Platform

Fri, 02 Dec 2016 08:45:00 EST

CULVER CITY, CA--(Marketwired - Dec 2, 2016) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first physical therapy telemedicine company to offer insurance reimbursable real-time distance monitored physical therapy (PT) treatments. The Company is pleased to announce the Company successfully signed its initial 3rd party PT clinic for the use of its PHZIO Tele- rehabilitation Platform. The agreement is with Back to Motion PT located in Denver Colorado. Back to Motion PT is one of our current universe of up to 30 beta site PT clinics to begin using our PHZIO system. The Company has a significant backlog of PT clinics who have indicated a high interest in using our PHZIO platform.

Avantor Unveils New Brand Identity

Thu, 01 Dec 2016 12:30:00 EST

Corporate logo and brand identity are reflective of Avantor's position as a growing, global supplier of high-purity life sciences and advanced technologies materials

Quark Venture Invests $4 Million in A New Technology That Harnesses the Body's Natural Immune System to Combat Disease

Thu, 01 Dec 2016 12:27:45 EST

GV and Quark Venture Join NanoDimension, Polaris Partners in supporting SQZ Biotech's breakthrough cell engineering technology

The Alliance for Regenerative Medicine Commends Passage of 21st Century Cures Act, Inclusion of Regenerative Medicine-Specific Provisions

Thu, 01 Dec 2016 10:31:01 EST

WASHINGTON, DC--(Marketwired - Dec 1, 2016) -  The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives' bipartisan passage of the 21st Century Cures Act.

IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product

Thu, 01 Dec 2016 09:56:08 EST

SAINT-LAURENT, CANADA--(Marketwired - Dec. 1, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today strengthened its relationship with Chemo Group ("Chemo") by signing a term sheet for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. According to Global Data, worldwide sales in 2015 of the CNS related product exceeded $4 billion.

Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

Thu, 01 Dec 2016 09:07:53 EST

MELBOURNE, AUSTRALIA--(Marketwired - Dec 1, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced that it has entered into a definitive agreement with U.S. institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares ("ADSs"), each representing one hundred and fifty (150) of the Company's Ordinary Shares, at a weighted average price of $1.25 per ADS. The Company will receive gross proceeds of approximately USD 6.0 million, before deducting customary offering expenses.

Oculus Innovative Sciences One Ups Itself, Meets Expectations Yet Again --

Thu, 01 Dec 2016 09:02:33 EST

REDONDO BEACH, CA--(Marketwired - Dec 1, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article examining the turnaround efforts of Oculus Innovative Sciences (NASDAQ: OCLS).

Ontario, Canada and South Korea Create $100M Global Commercialization Partnership

Thu, 01 Dec 2016 09:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Today MaRS Innovation (MI) and the Korea Health Industry Development Institute (KHIDI) signed a five year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations which is expected to generate new startups worth over $100M.

GeoVax Observes World AIDS Day

Thu, 01 Dec 2016 09:00:00 EST

Everyone Encouraged to Get Tested for HIV

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Thu, 01 Dec 2016 09:00:00 EST

Company Aiming to Produce 6-Month Breakthrough Data

Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma, Inc.

Thu, 01 Dec 2016 08:30:00 EST

NEW YORK, NY--(Marketwired - December 01, 2016) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Hemispherx Biopharma, Inc. (NYSE MKT: HEB). The full 60-page report is available on Crystal Research Associates' website at

Service Provider Loyalty Remains Strong as Lattice Biologics Announces Issuance of Common Shares

Thu, 01 Dec 2016 08:30:00 EST

Additionally, company to hold its Annual General Meeting in 2017

Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

Thu, 01 Dec 2016 08:00:00 EST

SEATTLE, WA--(Marketwired - Dec 1, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.

Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

Thu, 01 Dec 2016 08:00:00 EST

BOSTON, MA--(Marketwired - December 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced that it has appointed Claude Knopf as Senior Vice President and Chief Business Officer. Mr. Knopf is an accomplished executive in the biotech industry and brings to Pieris a demonstrable track record of success in strategy, corporate development, licensing, alliance management, marketing and sales spanning more than two decades.

Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

Thu, 01 Dec 2016 08:00:00 EST

VANCOUVER, BC--(Marketwired - December 01, 2016) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully obtained provincial formulary coverage from Alberta Health and Manitoba Health for VistitanT (bimatoprost 0.03% w/v, ophthalmic solution). Alberta Health have additionally listed VistitanT as interchangeable to Lumigan RC® for the purposes of its formulary coverage, giving Aequus rapid access to an existing market in Alberta. According to IMS data, Lumigan RC® sold over CND$5M in Alberta and Manitoba combined in 2015.

DiaMedica Announces the Sale and Transfer of its DM-71 Product for Type 2 Diabetes

Thu, 01 Dec 2016 08:00:00 EST

MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 1, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) today announced the sale and transfer of its DM-71 product and related intellectual property. The sale of this non-core asset provides DiaMedica with a total of $300,000 in upfront payments, of which $50,000 had been previously received, and a royalty stream linked to future sales.

Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

Thu, 01 Dec 2016 07:45:00 EST

LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.

Nlyte Hosts Leadership Technology Panel at Gartner Data Center Conference

Thu, 01 Dec 2016 07:15:00 EST

Company Facilitates Discussion with Dell, Social Security Administration, USAA, NASA and VMware Representatives on Data Center Priorities and Best Practices

Xtalks Announces its December 2016 Webinars

Thu, 01 Dec 2016 07:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Upcoming free, educational webinars from Xtalks Life Sciences will feature topics on ICH E6 (R2),Sales Enablement Strategy, Immunotherapy, Big Data, Orphan Drug Development and Remote Monitoring.

Dynavax to Webcast Cancer R&D Day on December 9, 2016

Thu, 01 Dec 2016 07:00:00 EST

BERKELEY, CA--(Marketwired - December 01, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Investor section of the company's website at

Akers Biosciences Signs Distribution Agreement with First Check Diagnostics for Rapid Cholesterol Test

Thu, 01 Dec 2016 07:00:00 EST

THOROFARE, NJ--(Marketwired - Dec 1, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed a distribution agreement with First Check Diagnostics, LLC ("First Check"), the major global diagnostic device and service provider, to serve as the exclusive distributor of the Company's rapid cholesterol self-test in the United States under their "First Check" brand.

Fennec Announces the Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate

Thu, 01 Dec 2016 06:00:00 EST

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Dec. 1, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children's Oncology Group, "Effects of Sodium Thiosulfate versus Observation on Development of Cisplatin-Induced Hearing Loss and Survival in Children with Cancer: Results from the Children's Oncology Group ACCL0431 Randomised Cohort Trial".

Vernalis plc: AGM Statement

Thu, 01 Dec 2016 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 1, 2016) - Vernalis plc (LSE: VER) (OTC PINK: VNLPY)

ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions

Wed, 30 Nov 2016 17:49:18 EST

Clinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa

ARUP Announces New CMO, Dr. Julio Delgado

Wed, 30 Nov 2016 16:50:42 EST

SALT LAKE CITY, UT--(Marketwired - November 30, 2016) - ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced the appointment of Julio Delgado, MD, MS, as chief medical officer (CMO), director of laboratories, and co-chief of the Clinical Pathology Division effective January 1, 2017. Delgado's appointment fills a vacancy left by the departure of Jerry Hussong, MD, DDS.

Valens Groworks Announces Private Placement and Stock Option Grant

Wed, 30 Nov 2016 15:28:46 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 30, 2016) -

SafetyChain Software to Showcase Food Safety & Quality Management Solutions at Food Safety Consortium in Schaumburg, IL

Wed, 30 Nov 2016 13:58:03 EST

Visit SafetyChain at Food Safety Tech's Annual Food Safety Consortium to learn how companies are improving their food safety and quality operations with SafetyChain

Cumulus Global Recognized on 2016 CRN Next-Gen 250 List

Wed, 30 Nov 2016 12:25:47 EST

Recognized for 4th Consecutive Year as a Trailblazing Solution Provider Transforming Business with Emerging Technologies

Pegasystems Named Silver Winner for Best New Product of the Year in Best in Biz Awards 2016

Wed, 30 Nov 2016 12:00:00 EST

Pega Customer Decision Hub honored for advanced decisioning and analytics capabilities